Wim J. Kirkels

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

Samantha Cambier, Richard Sylvester, Laurence Collette et al. · European Urology · 2015 · 640 citations · Full text

Medicine, Oncology, Urology +12

Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder

Richard Sylvester, Maurizio Brausi, Wim J. Kirkels et al. · European Urology · 2009 · 433 citations · Full text

Medicine, Oncology, Urology +13

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program

René Raaijmakers, Wim J. Kirkels, Monique J. Roobol et al. · Urology · 2002 · 404 citations

Medicine, Radiology, Urology +17

Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome

Bas W.G. van Rhijn, André N. Vis, Theodorus van der Kwast et al. · Journal of Clinical Oncology · 2003 · 321 citations

Medicine, Oncology, Pathology +15

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.

Bas W.G. van Rhijn, Irene Lurkin, François Radvanyi et al. · PubMed · 2001 · 309 citations

Medicine, Oncology, Urology +14